This meeting will explore today’s evolving strategies and technologies for improving the robustness of mammalian cell cultivation. From media enhancement and cell growth to scaling up, automation, and manufacturing, this leading cell culture meeting is designed to provide helpful information to optimize the job of growing cells.
Optimizing Cell Culture Technology will include talks from industry experts that address critical issues in an atmosphere that encourages sharing, learning, and networking. The agenda will again feature small-group breakout discussions that provide the opportunity to discuss important topics with your peers in a fun and collegial setting. In addition, case studies will be presented that shed light on improving yield while maintaining product quality within the regulatory framework.
Scientific Advisors
Susan Dana Jones, Ph.D., Vice President and Senior Consultant, BioProcess Technology Consultants
Dennis Kraichely, Ph.D., Associate Director, CMC Team Lead, Portfolio Management & Technical Integration, Johnson & Johnson Pharmaceutical R&D, Inc.
Robin Ng, Ph.D., Senior Bioengineer, Cell Culture Process Development, Shire Human Genetic Therapies
Fubao Wang, Ph.D., Senior Research Fellow, Vaccine & Biologics Research, Merck & Co.
Preliminary Agenda
Standard Settings for Cell Culture Reagents: USP Perspective
Fouad Atouf, Ph.D., Scientist, Biologics and Biotechnology, US Pharmacopeia
Manufacturing & Regulatory Issues for Ex Vivo Expanded Cell-Based Products
Scott R. Burger, Ph.D., Principal, Advanced Cell & Gene Therapy
Optimizing the Culture Environment through Cell Corpse Clearance
Christopher D. Gregory, Ph.D., Professor, Inflammatory Cell Biology, & Deputy Director, MRC Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh
Talk Title to be Announced
Lianchun Fan, Ph.D., Molecular and Cellular Biology, Bioproduct Research and Development, Eli Lilly and Company
Advantages of Dynamic 3-D Cell Culture
Rebecca Drumm, Cell Culture Scientist, KIYATEC, Inc.
Design of Experiment (DOE) in Cell Culture Condition Optimization
John (Jun) Yao, Ph.D., Group Leader, Upstream Process, Morphotek, Inc.
Single-Batch Production of Recombinant Human Polyclonal Antibodies
Christian Müller, Ph.D., Senior Scientist, Antibody Expression, Symphogen
Use of Twenty-Four Well Micro Bioreactor as a Scale-Down Model for Optimizing Cell Culture Process Development
Mark Kwatia, M.B.A., Biologics Process Development, Process Design R&D, Diagnostics Division, Abbott Laboratories
Development of Robust and Predictive Fed-Batch Scale-Down Models for CHO-S Cells Using Chemically Defined Basal Medium and Feeds
Mylène Talabardon, Ph.D., Group Manager, Upstream Processing, Biotech Process Sciences, Merck Serono
Improving Biotherapeutics Through the Use of RNAi
David Kocisko, Ph.D., Principal Scientist, Alnylam Pharmaceuticals
Effects of Bioreactor Design on Quality & Harvest
Speaker to be Announced
Automating Cell Culture Processes
Speaker to be Announced
The Culture and Cryopreservation of Human Corneal Epithelial Stem Cells for Transplantation
Sajjad Ahmad, Ph.D., Academic Clinical Lecturer, Institute of Human Genetics and North East England Stem Cell Institute, Newcastle University